Idorsia proposes CHF 120 million commercialization partnership for Tryvio/Jeraygo

Idorsia announced a proposed commercialization partnership with noteholders of its special purpose vehicle Idorsia Investments SARL to unlock the global commercial potential of the dual endothelin receptor antagonist Tryvio/Jeraygo (aprocitentan). The transaction involves CHF 120 million in funding, with noteholders providing CHF 72 million and Idorsia contributing CHF 48 million over two years.

Detected & updated continuously · Source: Nebula